Skip to content

Clary Sage Essential Oil & Pregnancy

Clary Sage Essential Oil Inhalation and Third Trimester Quality of Life: A Randomized, Double Blind, Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05000424
Enrollment
50
Registered
2021-08-11
Start date
2021-11-01
Completion date
2023-02-28
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Related, Quality of Life

Keywords

clary sage, essential oil, aromatherapy

Brief summary

The purpose of this study is to evaluate the potential for clary sage essential oil to support overall health, wellbeing, and quality of life during the third trimester of pregnancy among otherwise healthy adult women.

Detailed description

Women will be informed of the opportunity to participate through their care providers, childbirth educators, or doulas. If they meet inclusion criteria, they will be given a brochure describing the risks and benefits of the study and the informed consent paperwork. If they provide consent, they will be randomized to one of two groups: active essential oil and inert placebo. Both groups will receive a 4-ounce bottle of oil to apply daily during the third trimester of pregnancy. Those in the placebo group will be given an inert plant oil. Those in the intervention group will be given the same oil with the addition of clary sage essential oil.

Interventions

OTHERClary Sage Massage Oil

This massage oil contains clary sage oil. Five drops will be used daily.

OTHERInert Massage Oil

This massage oil consists entirely of plant based oils. Five drops will be used daily.

Sponsors

Nutraceuticals Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 20-39 * Lives in the United States * Pregnant, singleton * Low risk * Less than 27 weeks gestation

Exclusion criteria

* PCOS diagnosis * Uncontrolled Hypertension (i.e. systolic/diastolic blood pressure \> 140/90) * Gestational Diabetes * History of Preeclampsia * Preterm labor * Incompetent cervix * Allergy to salvia sclarea or related plants * Known Birth Defects * Thyroid Disease diagnosis

Design outcomes

Primary

MeasureTime frameDescription
Change in salivary estriol levels from pregnancy week 27 to pregnancy week 36.Pregnancy week 27 and 36salivary estriol levels are collected via the passive drool method and laboratory analyzed
Change in quality of life from week 27 to 36 of the pregnancy using the World Health Organization's Quality of Life, Brief-Form Scale (WHOQOL-BREF).Pregnancy week 27 and 36This one survey measures overall quality of life through. It contains 26 questions across 4 domains. Questions are scored on a 1-5 likert scale with higher scores indicating higher quality of life.

Secondary

MeasureTime frameDescription
Duration of Pregnancyfrom enrollment to birth, up to 16 weeksThe total length of the pregnancy (in days) from last menstrual period to birth.
Duration of phase 2 of laborfrom the onset of labor to birth, up to 24 hoursThe total length of phase 2 of labor (in minutes)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026